Regulation of Emergency Biotechnology Response Systems in China

1. Introduction

China’s emergency biotechnology response system is a legal and administrative framework designed to prevent, detect, control and respond to biological emergencies, including infectious disease outbreaks, laboratory accidents, dangerous pathogen releases and public health threats arising from biotechnology research. It combines public health legislation, biosafety regulation, emergency management, pharmaceutical regulation and scientific research oversight.

The framework is not governed by one single statute. Instead, it operates through several interconnected laws, regulations and administrative mechanisms. These establish responsibilities for government authorities, hospitals, research institutions, biotechnology companies and laboratories.

The central legal challenge is to balance rapid emergency intervention, public health protection, scientific research, individual rights and accountability. China’s experience with COVID-19, together with its broader biosafety legislation, illustrates how these competing objectives are addressed.

2. Principal legal framework

A. Biosecurity Law of the People’s Republic of China, 2021

The Biosecurity Law, which took effect on 15 April 2021, is a central component of China’s biological risk governance system.

Its main objectives include:

Preventing and controlling major new and emerging infectious diseases.

Regulating biotechnology research, development and application.

Strengthening biosafety management of pathogenic microorganisms.

Establishing mechanisms for biological risk monitoring, early warning and emergency response.

Protecting human health, ecological security and national biosecurity.

The law establishes responsibilities for relevant government departments and research entities to monitor biological risks, develop contingency arrangements and respond to biosecurity incidents.

It is particularly important when an emergency originates in a laboratory, involves dangerous biological materials or creates risks beyond an ordinary clinical outbreak.

B. Law on the Prevention and Treatment of Infectious Diseases

China’s Law on the Prevention and Treatment of Infectious Diseases provides the principal public health framework for identifying, reporting and controlling infectious disease outbreaks.

It regulates disease surveillance, diagnosis, reporting, prevention, treatment and the adoption of public health control measures. Depending on the circumstances and applicable legal requirements, authorities may implement isolation, quarantine, medical observation, disinfection and other measures to interrupt transmission.

The law is relevant to biotechnology emergencies when a genetically modified organism, engineered microorganism or other biological agent causes or threatens to cause infectious disease.

C. Emergency Response Law

The Emergency Response Law provides the general framework for preparing for and responding to emergencies. It addresses emergency planning, early warning, command arrangements, resource mobilisation and coordinated action by government agencies.

In a biotechnology emergency, it supports coordination among health authorities, emergency management departments, local governments, hospitals and relevant technical institutions.

Its operation must be read together with more specialised laws governing infectious diseases, laboratory biosafety and biosecurity.

D. Public Health Emergency Response Law, 2025

An important recent development is China’s Public Health Emergency Response Law, adopted on 12 September 2025 and effective from 1 November 2025. It provides a dedicated statutory framework for public health emergencies, including major infectious disease outbreaks, unexplained clusters of illness and mass poisoning incidents. 【turn492590search4】

The law strengthens emergency reporting, government coordination, early-warning arrangements, emergency preparedness and response accountability. It also establishes legal responsibilities for institutions and individuals involved in emergency response.

A particularly significant feature is the requirement for medical institutions and on-duty personnel to report actual or potential public health emergencies through the designated direct-reporting system within two hours. 【turn492590search8】

This legislation is especially relevant to biotechnology emergencies because delayed recognition of a novel pathogen can increase the consequences of an outbreak.

3. Institutional structure and emergency procedures

China’s emergency biotechnology response system involves several institutions:

National Health Commission: Coordinates public health policy and medical emergency measures.

National Disease Control and Prevention Administration: Supports disease surveillance, prevention and outbreak control.

Ministry of Emergency Management: Coordinates relevant emergency management and disaster-response functions.

National Medical Products Administration: Regulates medicines, vaccines and medical products, including applicable emergency authorisation and regulatory procedures.

Local governments and disease-control institutions: Conduct reporting, investigation, containment and local emergency implementation.

The operational process generally follows five stages.

Detection and reporting: Hospitals, laboratories and disease-control institutions identify unusual infections or biological incidents and report them through applicable channels.

Risk assessment and warning: Authorities investigate the threat, assess its severity and determine the appropriate level of response.

Emergency activation: Competent authorities coordinate medical resources, laboratories, protective equipment and other necessary supplies.

Containment and treatment: Authorities implement legally authorised public health measures and provide medical care.

Investigation and accountability: Authorities investigate the incident, examine possible regulatory failures and impose administrative, civil or criminal liability where legally justified.

The precise measures depend on the nature of the incident, the applicable statutory powers and the severity of the threat.

4. Regulation of emergency biotechnology products

Emergency responses may require rapid development and deployment of vaccines, diagnostic kits, antiviral medicines and biological countermeasures.

China’s Drug Administration Law and associated regulatory rules provide the framework for pharmaceutical quality, safety and regulatory oversight. Emergency circumstances may justify accelerated regulatory procedures where statutory conditions are met, but they do not automatically eliminate requirements concerning safety, manufacturing quality or clinical evidence.

The Biosecurity Law also regulates biotechnology research and pathogenic microorganism laboratories. Research institutions must comply with applicable biosafety controls, while serious biological incidents may trigger reporting, containment and investigative obligations.

The key distinction is that emergency response authority does not constitute unrestricted permission to conduct biotechnology experiments or distribute unapproved products.

5. Important cases and legal precedents

Directly reported Chinese judicial decisions specifically interpreting the Biosecurity Law’s emergency biotechnology provisions remain limited. Nevertheless, the following legal precedents and official accountability proceedings are important.

A. Li Wenliang incident, Wuhan, 2020

Dr Li Wenliang warned colleagues about a suspected SARS-like outbreak in Wuhan in late December 2019. Local police issued him a written reprimand on 3 January 2020 for allegedly spreading false information.

Following an investigation, Wuhan police withdrew the reprimand and apologised in March 2020. The investigation found that the handling of the matter was improper, involved incorrect application of the law and did not follow proper enforcement procedures. 【turn652704search7】

Legal significance: This was not a reported judicial judgment, but an official administrative accountability proceeding. It illustrates the dangers of mishandling early outbreak warnings and the importance of lawful enforcement, accurate information and institutional accountability.

B. Supreme People’s Court COVID-19 Guiding Opinions, 2020–2022

During the pandemic, the Supreme People’s Court issued guiding opinions addressing civil disputes arising from COVID-19, including contractual obligations, force majeure and the protection of lawful interests.

These opinions clarified how courts should handle disputes created by emergency restrictions and pandemic-related disruptions. 【turn652704search4】

Legal significance: They demonstrate how emergency measures can affect private rights and commercial obligations. They are judicial guidance rather than a single case establishing a biotechnology-specific precedent.

C. COVID-19-related judicial practice

Chinese courts also dealt with disputes concerning disrupted supply chains, contractual performance and emergency restrictions. The relevant principles require courts to examine the circumstances, causal connection and applicable legal rules rather than assume that every pandemic-related failure automatically constitutes force majeure.

These decisions are indirectly relevant to biotechnology companies supplying medicines, diagnostic equipment and emergency medical products.

6. Legal challenges and conclusion

China’s system combines central coordination, local implementation, biological risk management and specialised public health legislation. The 2025 Public Health Emergency Response Law and revised Infectious Disease Prevention and Control Law strengthen the legal framework for early warning and emergency accountability.

Nevertheless, important issues remain: ensuring prompt reporting, protecting scientific communication, maintaining transparency, safeguarding personal information and ensuring that emergency restrictions remain lawful and proportionate.

In conclusion, China’s emergency biotechnology response system is a multi-layered statutory framework rather than a single emergency mechanism. Its effectiveness depends not only on laboratory capacity and medical resources but also on timely disclosure, institutional coordination, regulatory compliance and accountability for misuse of emergency powers.